Učitavanje...

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

Evolocumab binds PCSK9, increasing low‐density lipoprotein cholesterol (LDL‐C) receptors and lowering LDL‐C. Target‐mediated evolocumab elimination is attributable to PCSK9 binding. As circulating PCSK9 and LDL‐C levels are primarily regulated by the liver, we compared evolocumab pharmacokinetics, p...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Pharmacol
Glavni autori: Gibbs, John P., Slatter, J. Greg, Egbuna, Ogo, Geller, Michelle, Hamilton, Lisa, Dias, Clapton S., Xu, Ren Y., Johnson, Jessica, Wasserman, Scott M., Emery, Maurice G.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363371/
https://ncbi.nlm.nih.gov/pubmed/27667740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.832
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!